Skip to content

Public FDA record

Z-0007-05: BC Thrombin Reagent . Thrombin Time Test

Recall record Z-0007-05 for Dade Behring , Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0007-05
Company in FDA record
Dade Behring , Inc.
FDA classification date
Oct 5, 2004
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 20, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

The product does not demonstrate the expected prolonged thrombin times for specimens obtained from patients recieving heparin

Source facts

Action
The recalling firm issued a recall letter dated 7/21/04 to their accounts informing them of the problem and the need to discard the product.
Initiated
2004-07-21
Root cause
Other
Terminated
2004-12-15
Distribution
The products were shipped to medical facilities in CT, FL, IA, IL, NJ, PA, and WI. The products were also shipped to Austria, Bosnia, Croatia, Hungry, Germany, Poland, Spain, RussiaFrance, Italy, Australia, Brazil, Canada, Saudi Arabia, El Salvador, and Turkey.
Recall number
Z-0007-05
Recall status
Terminated
CDRH record ID
34917
FDA classified
2004-10-05
Recall event number
29987

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗